Hussein El-Newihi, MD
Gastroenterology · El Centro, CANPI 1275580698
Payments from drug & device makers
Across 236 payments — averaging $24.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$902
- AbbVie$604
- Regeneron Healthcare Solutions, Inc.$569
- Ironwood Pharmaceuticals, Inc$516
- Madrigal Pharmaceuticals$425
- Ipsen Biopharmaceuticals, Inc$325
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,712100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 53 | $902 |
| AbbVie(2 entities) | 32 | $604 |
| Regeneron Healthcare Solutions, Inc. | 19 | $569 |
| Ironwood Pharmaceuticals, Inc | 25 | $516 |
| Madrigal Pharmaceuticals | 16 | $425 |
| Ipsen Biopharmaceuticals, Inc | 12 | $325 |
| Intercept Pharmaceuticals, Inc. | 15 | $321 |
| Phathom Pharmaceuticals, Inc. | 2 | $260 |
| Sanofi | 4 | $222 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $199 |
| Intuitive Surgical | 2 | $163 |
| E.r. Squibb & Sons, L.L.C. | 2 | $134 |
| Pfizer | 6 | $132 |
| Alfasigma USA, Inc. | 5 | $104 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $100 |
| Bristol Myers Squibb | 5 | $84 |
| GSK | 2 | $77 |
| Alnylam Pharmaceuticals Inc. | 3 | $76 |
| Shionogi Inc | 4 | $73 |
| Medtronic | 1 | $72 |
| Nestle Healthcare Nutrition Inc. | 3 | $65 |
| Merck | 3 | $57 |
| Celltrion USA Inc. | 2 | $45 |
| Ferring Pharmaceuticals Inc. | 2 | $45 |
| Redhill Biopharma Inc. | 2 | $38 |
| Gilead | 2 | $31 |
| Novo Nordisk | 1 | $31 |
| Daiichi Sankyo Inc. | 2 | $29 |
| UCB, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,721 in reported general payments places this provider in the 65th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcalivaObeticholic Acid | 31 | $280,444 |
| LinzessLinaclotide | 122 | $95,344 |
| Cimzia (2 Pack)Certolizumab Pegol | 13 | $69,589 |
| CreonLipase/Protease/Amylase | 21 | $52,352 |
| XifaxanRifaximin | 12 | $35,754 |
| TrulancePlecanatide | 52 | $34,700 |
| MovantikNaloxegol Oxalate | 67 | $34,347 |
| Dexlansoprazole DrDexlansoprazole | 109 | $33,986 |
| Mesalamine | 36 | $25,756 |
| Ursodiol | 78 | $12,743 |
| Sucralfate | 220 | $12,406 |
| Omeprazole | 1,141 | $12,162 |
| Mesalamine DrMesalamine | 20 | $11,743 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 588 | $8,956 |
| Dicyclomine Hcl | 300 | $7,824 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Intercept Pharmaceuticals, Inc.Ocaliva | $321 | $280,44431 claims |
| AbbVieLinzess, Creon | $604 | $147,697143 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $902 | $70,45464 claims |
| UCB, Inc.Cimzia (2 Pack) | $22 | $69,58913 claims |
| Redhill Biopharma Inc.Movantik | $38 | $34,34767 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,885 gastroenterology providers in California.
Other gastroenterology in El Centro
- Peter WinkleCypress$116.7M
- Manuchehr DaraniSanta Ana$17.7M
- Jatinder PruthiLancaster$4.4M
- Long DangWestminster$4.3M
- Muhammad SheikhFresno$4.3M
- Gregory WienerChula Vista$3.5M
- Gil MelmedLos Angeles$3M
- Christopher BowlusSacramento$3M
- Bennett RothLos Angeles$2.8M
- Brigid BolandSan Diego$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.